437 related articles for article (PubMed ID: 26885650)
1. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis.
Koster MJ; Matteson EL; Warrington KJ
Curr Opin Rheumatol; 2016 May; 28(3):211-7. PubMed ID: 26885650
[TBL] [Abstract][Full Text] [Related]
2. [Recent advances in the treatment of large vessel vasculitides].
Szabó MZ; Kiss E
Orv Hetil; 2017 Jan; 158(1):5-12. PubMed ID: 28067080
[TBL] [Abstract][Full Text] [Related]
3. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab: a new therapy for large vessel vasculitis.
Al-Homood IA
Clin Exp Med; 2014 Nov; 14(4):355-60. PubMed ID: 23949338
[TBL] [Abstract][Full Text] [Related]
5. Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.
Matsumoto K; Suzuki K; Yoshimoto K; Seki N; Tsujimoto H; Chiba K; Takeuchi T
Arthritis Res Ther; 2019 Dec; 21(1):304. PubMed ID: 31888748
[TBL] [Abstract][Full Text] [Related]
6. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity?
Furuta S; Cousins C; Chaudhry A; Jayne D
J Rheumatol; 2015 Feb; 42(2):300-8. PubMed ID: 25399386
[TBL] [Abstract][Full Text] [Related]
8. Biotherapies in large vessel vasculitis.
Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
[TBL] [Abstract][Full Text] [Related]
9. [Giant-cell arteritis and Takayasu arteritis: epidemiological, diagnostic and treatment aspects].
Chaigne-Delalande S; de Menthon M; Lazaro E; Mahr A
Presse Med; 2012 Oct; 41(10):955-65. PubMed ID: 22940467
[TBL] [Abstract][Full Text] [Related]
10. Management of large-vessel vasculitis.
Salvarani C; Hatemi G
Curr Opin Rheumatol; 2019 Jan; 31(1):25-31. PubMed ID: 30461542
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
Saito S; Okuyama A; Okada Y; Shibata A; Sakai R; Kurasawa T; Kondo T; Takei H; Amano K
Rheumatology (Oxford); 2020 Jul; 59(7):1617-1621. PubMed ID: 31665468
[TBL] [Abstract][Full Text] [Related]
12. [Large vessel vasculitis : Giant cell arteritis and Takayasu arteritis].
Villiger PM
Z Rheumatol; 2017 Aug; 76(6):509-523. PubMed ID: 28638968
[TBL] [Abstract][Full Text] [Related]
13. New Therapeutic Approaches to Large-Vessel Vasculitis.
Kaymakci MS; Warrington KJ; Kermani TA
Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience.
Yoshida M; Watanabe R; Ishii T; Machiyama T; Akita K; Fujita Y; Shirota Y; Sugimura K; Fujii H; Shimokawa H; Harigae H
Int J Rheum Dis; 2016 Jan; 19(1):87-94. PubMed ID: 26443306
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the diagnosis and therapy of large vessel vasculitis.
Keser G; Atagunduz P; Soy M
Pol Arch Intern Med; 2022 Jun; 132(6):. PubMed ID: 35699647
[TBL] [Abstract][Full Text] [Related]
16. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
17. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.
Águeda AF; Monti S; Luqmani RA; Buttgereit F; Cid M; Dasgupta B; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
RMD Open; 2019; 5(2):e001020. PubMed ID: 31673416
[TBL] [Abstract][Full Text] [Related]
18. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
Osman M; Pagnoux C; Dryden DM; Storie D; Yacyshyn E
PLoS One; 2014; 9(12):e115026. PubMed ID: 25517966
[TBL] [Abstract][Full Text] [Related]
19. Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.
Sreih AG; Alibaz-Oner F; Kermani TA; Aydin SZ; Cronholm PF; Davis T; Easley E; Gul A; Mahr A; McAlear CA; Milman N; Robson JC; Tomasson G; Direskeneli H; Merkel PA
J Rheumatol; 2017 Dec; 44(12):1933-1937. PubMed ID: 28864646
[TBL] [Abstract][Full Text] [Related]
20. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
Muratore F; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2017 Apr; 13(4):345-360. PubMed ID: 28116918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
